This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.

Inclusion Criteria:

1. Signed informed consent;
2. Adult ≥ 18 years of age;
3. ECOG performance status score ≤ 2;
4. Life expectancy of not less than 12 weeks;
5. Histopathologically confirmed diagnosis of PTCL;
6. Presence of measurable disease;
7. Adequate bone marrow function and vital organ function reserve;
8. Ability to comply with study requirements and to complete study-related procedures;
9. Adequate contraception during participation in the trial.

Exclusion Criteria:

1. Presence of unresolved drug-related adverse events greater than Grade 1;
2. Lymphoma involving the central nervous system;
3. Failure to complete the required washout period for other anti-tumor therapies;
4. Corticosteroid use that does not meet protocol requirements;
5. Major surgery/trauma within a short period, or planned major surgery within a short period;
6. Vaccination with a live vaccine within a short period;
7. Inability to discontinue prohibited medications;
8. Requirement for immunosuppressive agents or biologics due to an underlying disease;
9. Presence of active infection;
10. Significant cardiovascular disease;
11. Presence of gastrointestinal disease that might affect drug intake or absorption;
12. History of other malignancies;
13. Known allergy to the study drug;
14. Other severe or uncontrolled systemic diseases;
15. Personnel with a conflict of interest (e.g., site staff, sponsor employees);
16. Pregnant or breastfeeding women;
17. Inability to comply with protocol requirements.